Biopharmaceutic planning in pediatric drug development

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 519-522

  Purohit, Vivek S ^a  

^a PFIZER INC   (United States)

Author keywords

bioavailability; bioequivalence; biopharmaceutics; formulations; pediatric

Indexed keywords

AGE; ARTICLE; BIOPHARMACEUTICAL PLANNING; CLINICAL STUDY; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG MARKETING; DRUG RESEARCH; INFORMATION RETRIEVAL; PEDIATRIC DRUG DEVELOPMENT; PEDIATRICS; PHARMACEUTICS; PROGRAM DEVELOPMENT; RISK ASSESSMENT; STRATEGIC PLANNING;

BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CHILD; HUMANS; PEDIATRICS; PLANNING TECHNIQUES; THERAPEUTIC EQUIVALENCY;

EID: 84862761437     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9364-3     Document Type: Article

References (11)

1. Pediatric Research Equity Act of 2007, Title IV. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM049870.pdf. Accessed on: 17 Jan 2012.
2. Best Pharmaceuticals for Children Act of 2007, Title V. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM049870.pdf. Accessed on 17 Jan 2012.
3. Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of December 12, 2006, on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg-2006-1901/reg-2006-1901-en. pdf. Accessed on 17 Jan 2012.
4. MS Benedetti R Whomsley EL Baltes 2005 Differences in absorption, distribution, metabolism and excretion of xenobiotics between the pediatric and adult populations Expert Opin Drug Metab Toxicol 1 3 447 471 10.1517/17425255.1.3.447
5. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 359 1157 1167
6. TN Johnson M Thomson 2008 Intestinal metabolism and transport of drugs in children: the effects of age and disease J Pediatr Gastroenterol Nutr 47 3 10 18607262 10.1097/MPG.0b013e31816a8cca 1:CAS:528:DC%2BD1cXot1yls7c%3D
7. M Roth-Cline J Gerson P Bright CS Lee RM Nelson 2011 Ethical considerations in conducting pediatric research. pediatric clinical pharmacology Handb Exp Pharmacol 205 Part 2 219 244 21882114 10.1007/978-3-642-20195-0-11
8. SH Haidar B Davit ML Chen D Conner L Lee QH Li, et al. 2008 Bioequivalence approaches for highly variable drugs and drug products Pharm Res 25 237 241 17891552 10.1007/s11095-007-9434-x 1:CAS:528:DC%2BD1cXkslSlsg%3D%3D
9. JA Cook BM Davit JE Polli 2010 Impact of biopharmaceutics classification system-based biowaivers Mol Pharm 7 1539 1544 10.1021/mp1001747 1:CAS:528:DC%2BC3cXhtFWrurjN
10. Tanguay M, Potvin D, Haddad J, Lavigne J, Marier JF, DiMarco M, et al. When will a drug formulation pass or fail bioequivalence criteria? Experience from 1,200 studies. AAPS Pharm Sci. 2002;4(S1). Abstract R6193.
11. Purohit VS, Harnisch L, Gao X. Relative bioavailability of different sildenafil formulations: a population pharmacokinetic based approach. Abstract R6349. AAPS Annual Meeting, 2011, Washington DC. Available from: www.aapsj.org/abstracts/AM-2011/R6349.pdf.